Wells Fargo & Company Aldeyra Therapeutics, Inc. Put Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ALDX
# of Institutions
107Shares Held
35.4MCall Options Held
104KPut Options Held
88.1K-
Perceptive Advisors LLC New York, NY8.59MShares$32.8 Million0.59% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$20.9 Million11.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$14.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.31MShares$12.6 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.32MShares$5.04 Million0.09% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $223M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...